Elevated Spinal Cyclooxygenase and Prostaglandin Release During Hyperalgesia in Diabetic Rats
- 1 July 2002
- journal article
- Published by American Diabetes Association in Diabetes
- Vol. 51 (7) , 2249-2255
Abstract
Diabetic rats display exaggerated hyperalgesic behavior in response to noxious stimuli that may model aspects of painful diabetic neuropathy. This study examined the contribution of spinal prostaglandin production to this exaggerated hyperalgesic behavior. Rats were implanted with spinal dialysis probes and received noxious stimulation to the hind paw by subcutaneous injection of 0.5% formalin solution. Prostaglandin E2 (PGE2) was measured in dialysates of lumbar spinal cerebrospinal fluid concurrent with behavioral responses to formalin injection. In separate experiments, formalin-evoked behavioral responses were measured after intrathecal delivery of either a cyclooxygenase inhibitor or an EP1 receptor antagonist, and cyclooxygenase protein was measured in spinal cord homogenates. Diabetic rats exhibited exaggerated behavioral responses to paw formalin injection and a concurrent prolongation of formalin-evoked PGE2 release. Formalin-evoked behavioral responses were dose-dependently reduced in diabetic rats by spinal delivery of a cyclooxygenase inhibitor or an EP1 receptor antagonist. Protein levels of cyclooxygenase-2 were elevated in the spinal cord of diabetic rats, whereas cyclooxygenase-1 protein was reduced. Hyperalgesic behavior in diabetic rats is associated with both increased cyclooxygenase-2 protein and cyclooxygenase-mediated PGE2 release. Spinal delivery of selective inhibitors of cyclooxygenase-2 or antagonists of prostaglandin receptors may have therapeutic potential for treating painful diabetic neuropathy.Keywords
This publication has 48 references indexed in Scilit:
- Spinal-cord involvement in diabetic peripheral neuropathyThe Lancet, 2001
- High glucose enhances IL-1β-induced cyclooxygenase-2 expression in rat vascular smooth muscle cellsLife Sciences, 2000
- CYCLOOXYGENASES 1 AND 2Annual Review of Pharmacology and Toxicology, 1998
- The reduction of antinociceptive effect of morphine administered intraventricularly is correlated with the decrease of serotonin release from the spinal cord in streptozotocin-induced diabetic ratsGeneral Pharmacology: The Vascular System, 1996
- Formalin-evoked activity in identified primary afferent fibers: systemic lidocaine suppresses phase-2 activityPain, 1996
- Tolrestat treatment prevents modification of the formalin test model of prolonged pain in hyperglycemic ratsPain, 1994
- Anti-nociceptive effects of the GM1 ganglioside derivative AGF 44 on the formalin test in normal and streptozotocin-diabetic ratsNeuroscience Letters, 1993
- Comparison of the Antinociceptive Effects of Pre- and Posttreatment with Intrathecal Morphine and MK801, an NMDA Antagonist, on the Formalin Test in the RatAnesthesiology, 1992
- Stereospecific effects of a nonpeptidic NK1 selective antagonist, CP-96,345: Antinociception in the absence of motor dysfunctionLife Sciences, 1991
- Pathological changes in the central and peripheral nervous system of young long-term diabeticsDiabetologia, 1968